Loading...
Please wait, while we are loading the content...
Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies
| Content Provider | Oxford Academic |
|---|---|
| Author | Yetmar, Zachary A Khodadadi, Ryan B Seville, Maria Teresa Brumble, Lisa O’Horo, John C Ganesh, Ravindra Razonable, Raymund R |
| Copyright Year | 2022 |
| Abstract | Antispike monoclonal antibody treatment of 180 B-cell-depleted patients with mild-to-moderate coronavirus disease 2019 (COVID-19) resulted in good outcomes overall, with only 12.2% progressing to severe disease, 9.4% requiring hospitalization, 0.6% requiring mechanical ventilation, no deaths within 30 days, and 1.8% developing persistent COVID-19. Antispike monoclonal antibodies appear effective in this immunocompromised population. |
| Related Links | https://academic.oup.com/ofid/article-pdf/9/7/ofac204/45028711/ofac204.pdf |
| File Format | |
| e-ISSN | 23288957 |
| DOI | 10.1093/ofid/ofac204 |
| Journal | Open Forum Infectious Diseases |
| Issue Number | 7 |
| Volume Number | 9 |
| Language | English |
| Publisher | Oxford Academic |
| Publisher Date | 2022-07-04 |
| Access Restriction | Open |
| Subject Keyword | Clinical Medicine Infectious Diseases Medicine and Health Anti-cd20 Covid-19 Monoclonal Antibody Rituximab Sars-cov-2 |
| Content Type | Text |
| Resource Type | Article |
| Subject | Oncology Infectious Diseases |